Objective: To explore whether transient ischemic attack (TIA) is significantly associated with subsequent cerebral infarction. Methods: A total of 415 patients were enrolled in this study and were divided into TIA (n = 205) and control group (n = 210), based on presence or absence of TIA before the ischemic cerebral infarction occurrence. The cerebral infarct volume and Neurological deficit scores were compared between the two groups. Furthermore, multiple linear model analysis was conducted to evaluate the impact of TIA on the volume of infarction and Neurological deficit scores in patients who had TIA before. Results: The volume of cerebral infarction and Neurological deficit scores in patients with TIA were significantly lower than those of the control group (P < 0.05). TIA duration, TIA frequency, level of Homocysteine and Hypersensitive C-reactive protein were significantly associated with the volume of cerebral infarction and Neurological deficit scores (P < 0.05). Conclusion: Prior TIA may have a positive impact on the cells of brain. The duration and frequency of TIA and level of Homocysteine and Hypersensitive C-reactive protein are independent risk factors of the volume of cerebral infarction and Neurological deficit scores.
K. Kitagawa, M. T. Matsumoto, et al. “Ischemic tolerance” phe-nomenon found in the brain. Brain Research, 1990, 528(1): 21-24.
J. Moncaya, G. R. De Freitas, J. Bogousslavsky, et al. Do transient ischemic attacks have a neuroprotective effect? Neurology, 2000, 54(11): 2089-2094.
T. Masada, Y. Hua, G. Xi, et al. At-tenuation of ischemic brain edema and cerebrovascular injury after ischemic preconditioning in the rat. Journal of Cerebral Flow and Me-tabolism, 2001, 21(1): 22-33.
J. M. Pradillo, D. Fernández-Lopez, I. Garcia-Yébenes, et al. Toll-like receptor 4 is involved in neuroprotec-tion afforded by ischemic preconditioning. Journal of Neurochemistry, 2009, 109(1): 287-294.
U. Dirnagl, K. Becker and A. Meisel. Preconditioning and tolerance against cerebral ischaemia: From ex-perimental strategies to clinical use. Lancet Neurology, 2009, 8(4): 398-412.